Publications
View and download slide summaries of the latest original articles focusing on cytokine signalling therapies within rheumatoid arthritis. All materials produced by the CSF team are subsequently reviewed and approved by individual Steering Committee members.
Identification of Two Tofacitinib Subpopulations with Different Relative Risk Versus TNF Inhibitors: An Analysis of the Open Label, Randomised Controlled Study ORAL Surveillance
Ann Rheum Dis. 2023 doi: 10.1136/ard-2022-223715 Epub ahead of print
Findings from a post hoc analysis of ORAL Surveillance can help guide individualised benefit/risk assessment and clinical decision-making on treatment with tofacitinib, based on identification of subpopulations ‘at risk’.
Keywords:
Association Between Baseline Cardiovascular Risk and Incidence Rates of Major Adverse Cardiovascular Events and Malignancies in Patients with Psoriatic Arthritis and Psoriasis Receiving Tofacitinib
Ther Adv Musculoskelet Dis. 2023 doi: 10.1177/1759720X221149965
Baseline 10-year atherosclerotic cardiovascular disease risk and metabolic syndrome are potentially associated with the incidence of both MACE and malignancies in patients receiving TOFA in the PsA and PsO clinical trial programs. This post hoc analysis aimed to examine the baseline CV disease risk and its association with the occurrence of MACE and malignancies in TOFA-treated patients with PsA and PsO.
Keywords:
Efficacy And Safety of Risankizumab for Active Psoriatic Arthritis: 52-Week Results from the Keepsake 1 Study
Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac607
Risankizumab (RZB) improves the signs and symptoms of PsA, with efficacy maintained through 52 weeks. Alongside the efficacy data, this analysis of KEEPsAKE 1 also evaluates the safety and tolerability profile of RZB.
Keywords:
Efficacy and Safety of Ixekizumab Versus Adalimumab in Biologic-naïve Patients with Active Psoriatic Arthritis and Moderate-to-severe Psoriasis: 52-week Results from the Randomized SPIRIT-H2H Trial
Dermatol Pract Concept. 2022 doi: 10.5826/dpc.1202a104
Ixekizumab (IXE)-treated patients achieved significantly greater simultaneous PASI100 and ACR50 responses through W52 versus adalimumab (ADA)-treated, confirming IXE as an efficacious and safe treatment. This study investigated the efficacy and safety of IXE and ADA in the subgroup of patients with PsA and moderate-to-severe PsO through W52.
Keywords:
Risankizumab Improved Health-Related Quality of Life, Fatigue, Pain and Work Productivity in Psoriatic Arthritis: Results Of Keepsake 1
Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac342
In this study risankizumab treatment resulted in greater improvements in fatigue and pain than placebo. Prior to this finding the study aimed to evaluate the impact of risankizumab on HRQoL and other PROs among patients with active PsA and inadequate response or intolerance to csDMARD-IR in the KEEPsAKE 1 trial.